Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon vs placebo in Delayed Sleep-Wake Phase Disorder
2021-005475-40Phase 3Active
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delayed sleep-wake phase disorder (DSPD) comparing Tasimelteon 20 mg with Placebo (2 arms). Primary endpoint: Sleep onset (change from baseline) by sleep diary. Started Jan 2022; status: active.
02
Drugs
tasimelteon
03
Conditions
delayed sleep-wake phase disorder (DSPD)
Beyond the preview
Go deeper on 2021-005475-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005475-40.